VirologyApril 24, 20265 min readUpdated August 24, 2026

Q-Bank Breakdown: HPV & cervical cancer — Why Every Answer Choice Matters

Koilocytosis and full-thickness cervical dysplasia point to high-risk HPV, where E6 and E7 disable p53 and Rb. The key is ruling out viral look-alikes.

You’re doing a Q-bank and get a cervical cancer question… and it feels “too easy.” HPV. Pap smear. Vaccine. Move on. But the real score gains come from understanding why each wrong answer is wrong—because NBME-style questions love swapping in near-miss distractors (HSV, EBV, adenovirus, polyomavirus, etc.). Let’s break down a classic vignette the way you should in your head on test day.


Clinical Vignette (Q-bank style)

A 32-year-old woman presents for routine screening. She has had multiple sexual partners and inconsistent condom use. Her Pap smear shows koilocytosis. Colposcopy reveals a high-grade lesion. Biopsy demonstrates dysplasia involving the full thickness of the epithelium. Which of the following best explains the pathogenesis of this condition?

A. Viral E6 and E7 proteins inactivate p53 and Rb tumor suppressor proteins
B. Viral thymidine kinase allows replication in nondividing cells
C. Virus establishes latency in sensory ganglia with periodic reactivation
D. Viral integration causes constitutive activation of NF-κB via Tax protein
E. Virus infects B cells and drives polyclonal activation via CD21 binding


Step-by-Step: What the Stem Is Screaming

Key clues

  • Koilocytosis → classic for HPV infection (perinuclear clearing + nuclear atypia)
  • High-grade lesion + full thickness dysplasia → CIN III / carcinoma in situ
  • Risk factors: multiple partners, inconsistent barrier protection

Diagnosis shortcut

HPV (especially 16, 18) → cervical intraepithelial neoplasia and cervical squamous cell carcinoma.


Correct Answer: A. E6 and E7 inactivate p53 and Rb

High-risk HPV types (most famously 16 and 18, also 31, 33, 45) are oncogenic because they disrupt cell-cycle checkpoints:

The two viral oncoproteins you must know

  • E6 → binds/inactivates p53 → ↓ apoptosis + impaired DNA damage arrest
    • Also increases telomerase (hTERT) activity (high-yield association)
  • E7 → binds/inactivates Rb → releases E2F → pushes cell into S phase

Why integration matters (high-yield nuance)

  • In high-risk HPV, viral DNA often integrates into the host genome.
  • Integration disrupts the E2 gene (a regulator that normally restrains E6/E7), leading to overexpression of E6/E7 → malignant progression.

What You’re Expected to Recognize (HPV High-Yield)

HPV basics (USMLE-friendly)

  • Nonenveloped, icosahedral, dsDNA virus
  • Replicates in the nucleus
  • Causes:
    • Anogenital warts (low-risk types 6, 11)
    • Cervical cancer (high-risk types 16, 18)
    • Other cancers: oropharyngeal squamous cell carcinoma (esp. HPV-16)

Koilocytes = buzzword

  • Squamous epithelial cells with:
    • Perinuclear halo
    • Enlarged, hyperchromatic nuclei

Distractor Autopsy: Why Each Wrong Answer Is Wrong

B. Viral thymidine kinase allows replication in nondividing cells

This is pointing to HSV (and to a lesser extent VZV).

  • HSV has thymidine kinase, which is why acyclovir works (it’s phosphorylated by viral TK).
  • HPV does not rely on thymidine kinase as its defining feature.
  • HPV’s oncogenesis is driven by E6/E7, not by a drug-target enzyme.

Test-day tip: If you see “thymidine kinase” in an answer choice, your brain should immediately think HSV/VZV + acyclovir.


C. Virus establishes latency in sensory ganglia with periodic reactivation

Also classic HSV (and VZV).

  • HSV-1: trigeminal ganglia
  • HSV-2: sacral ganglia
  • VZV: dorsal root ganglia

HPV does infect basal epithelial cells and can persist, but it’s not a “sensory ganglion latency/reactivation” virus.

How they trick you: Cervical lesions + STI risk factors can bait HSV, but HSV is more about painful vesicular lesions, not koilocytosis/CIN.


D. Viral integration causes constitutive activation of NF-κB via Tax protein

This is HTLV-1.

  • HTLV-1 is an enveloped ssRNA retrovirus (diploid), uses reverse transcriptase
  • Tax activates transcription (including IL-2) and promotes T-cell proliferation
  • Associated with:
    • Adult T-cell leukemia/lymphoma
    • Tropical spastic paraparesis

HPV integrates too, but Tax/NF-κB is not HPV’s mechanism. HPV’s key proteins are E6/E7.


E. Virus infects B cells and drives polyclonal activation via CD21 binding

This is EBV.

  • EBV infects B cells via CD21 (CR2)
  • Causes:
    • Infectious mononucleosis (posterior cervical LAD, splenomegaly)
    • Burkitt lymphoma (t(8;14), c-myc)
    • Hodgkin lymphoma (some cases)
    • Nasopharyngeal carcinoma

Cervical squamous dysplasia/cancer is not driven by EBV; it’s an HPV story.

Another classic EBV distractor: “heterophile-positive” or “atypical lymphocytes (reactive CD8+ T cells)” would steer you to EBV—not here.


Rapid-Fire Comparison Table (Great for Elimination)

VirusGenome/EnvelopeKey Mechanism/BuzzwordClassic Diseases
HPV (16/18)dsDNA, nonenvelopedE6 (p53), E7 (Rb); koilocytesCIN, cervical cancer, oropharyngeal SCC
HPV (6/11)dsDNA, nonenvelopedBenign proliferationCondyloma acuminata, laryngeal papillomas
HSV-1/2dsDNA, envelopedLatency in sensory ganglia; viral TKPainful vesicles, encephalitis (HSV-1), neonatal herpes (HSV-2)
EBVdsDNA, envelopedInfects B cells via CD21Mono, Burkitt, some Hodgkin, NPC
HTLV-1ssRNA-RT, envelopedTax → T-cell proliferationAdult T-cell leukemia/lymphoma

USMLE High-Yield Add-Ons (Common Follow-Up Questions)

1) Screening logic (Step 2 vibe)

  • Pap screening typically starts at age 21 (US guidelines commonly tested in broad strokes)
  • HPV testing co-testing increases with age (details vary by guideline updates—know the general principle: screen + triage)

2) Vaccine points (Step 1 + Step 2)

  • Gardasil 9 protects against:
    • High-risk: 16, 18, 31, 33, 45, 52, 58
    • Low-risk: 6, 11
  • It’s prophylactic, not therapeutic (prevents infection; doesn’t treat established lesions)

3) Morphology and progression (path tie-in)

  • CIN I: lower 1/3 of epithelium (often transient HPV)
  • CIN II/III: increasing thickness involvement, higher malignant potential
  • Carcinoma in situ (CIN III): full thickness dysplasia, basement membrane intact
  • Invasive cancer crosses the basement membrane

Take-Home “Answer Choice Mindset”

When the stem gives you koilocytosis + cervical dysplasia, lock onto HPV—then choose the mechanism that matches high-risk HPV oncogenesis:

  • High-risk HPV → E6 inhibits p53; E7 inhibits Rb
  • Everything else is a “different virus with a different signature move.”

If you train yourself to recognize what each distractor is trying to be, you’ll start getting questions right even when the stem is messy.

Frequently Asked Questions

Why does HPV cause cervical dysplasia and cervical cancer?

High-risk HPV causes cervical dysplasia and cancer through its E6 and E7 oncoproteins. E6 inactivates p53, which reduces apoptosis and impairs DNA damage arrest, and it also increases telomerase activity. E7 inactivates Rb, releasing E2F and pushing the cell into S phase. In high-risk HPV infection, viral DNA often integrates into the host genome, disrupts E2, and leads to overexpression of E6 and E7.

What does koilocytosis mean on a Pap smear?

Koilocytosis is a classic clue for HPV infection. It refers to squamous epithelial cells with perinuclear clearing that creates a halo, along with enlarged, hyperchromatic nuclei. In a cervical screening vignette, koilocytosis strongly points toward HPV rather than other viral distractors, especially when it appears with a high-grade lesion or full-thickness dysplasia.

How do you tell HPV cervical lesions from HSV in a question stem?

HPV is suggested by koilocytosis and cervical intraepithelial neoplasia, whereas HSV is suggested by painful vesicular lesions, sensory ganglion latency, and thymidine kinase. HSV establishes latency in trigeminal or sacral ganglia and is linked to viral thymidine kinase, which is why acyclovir works. HPV instead infects basal epithelial cells and causes oncogenesis through E6 and E7, not thymidine kinase or ganglion reactivation.

How do you distinguish HPV from EBV and HTLV-1 on exams?

HPV is identified by koilocytes, cervical dysplasia, and E6 and E7 mediated inactivation of p53 and Rb. EBV instead infects B cells via CD21 and is associated with infectious mononucleosis, Burkitt lymphoma, some Hodgkin lymphoma, and nasopharyngeal carcinoma. HTLV-1 is an enveloped ssRNA retrovirus that uses Tax to activate transcription and promote T-cell proliferation, leading to adult T-cell leukemia lymphoma and tropical spastic paraparesis.

What HPV types are high-yield to know for cervical cancer versus genital warts?

HPV 16 and 18 are the classic high-risk types associated with cervical intraepithelial neoplasia and cervical squamous cell carcinoma. The same high-yield group also includes 31, 33, and 45 as oncogenic types. In contrast, HPV 6 and 11 are low-risk types that cause anogenital warts and laryngeal papillomas, reflecting benign proliferation rather than malignant transformation.

Try free Infectious Disease questions

Reading about a topic is not the same as being tested on it. Answer a real Infectious Disease question from the StepGenie qbank with no account, and see the full step-by-step explanation. Then build practice sets around the systems you score worst in, so the weak areas your qbank flags are the ones you actually drill.